vTv Therapeutics Inc.VTVT is a clinical-stage biopharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on VTVT's earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that vTv Therapeutics could be a solid choice for investors.
Current Quarter Estimates for VTVT
In the past 60 days, two estimates have gone higher for vTv Therapeutics while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of 42 cents a share 60 days ago, to a loss of 40 cents today, a move of 4.8%.
Current Year Estimates for VTVT
Meanwhile, vTv Therapeutics' current year figures are also looking quite promising, with three estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of $1.41 per share 60 days ago to a loss of $1.21 per share today, a move of 14.2%.
vTv Therapeutics Inc. Price and Consensus
The stock has also started to move higher lately, adding 21.6% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #3 (Hold) stock to profit in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.